Time course of bone mineral density changes during 4-year rituximab therapy in postmenopausal women with rheumatoid arthritis

Objective: to estimate the time course of bone mineral density (BMD) changes during 4-year rituximab (RTM) therapy in postmenopausal women with rheumatoid arthritis (RA).Subjects and methods. Seventy-nine postmenopausal women with a valid diagnosis of RA were followed up. According to the basic ther...

Full description

Saved in:
Bibliographic Details
Main Authors: T. A. Raskina, M. V. Koroleva, I. S. Dydykina, O. S. Malyshenko, G. A. Pintova
Format: Article
Language:Russian
Published: IMA-PRESS LLC 2015-09-01
Series:Современная ревматология
Subjects:
Online Access:https://mrj.ima-press.net/mrj/article/view/633
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849303381795930112
author T. A. Raskina
M. V. Koroleva
I. S. Dydykina
O. S. Malyshenko
G. A. Pintova
author_facet T. A. Raskina
M. V. Koroleva
I. S. Dydykina
O. S. Malyshenko
G. A. Pintova
author_sort T. A. Raskina
collection DOAJ
description Objective: to estimate the time course of bone mineral density (BMD) changes during 4-year rituximab (RTM) therapy in postmenopausal women with rheumatoid arthritis (RA).Subjects and methods. Seventy-nine postmenopausal women with a valid diagnosis of RA were followed up. According to the basic therapy option, all the patients were allocated into two groups: 1) 44 patients who received combination therapy with RTM and methotrexate (MT); 2) 35 patients who had MT monotherapy. BMD was estimated by dual-energy X-ray absorptiometry using an Excell XR-46 stationary dualenergy X-ray bone densitometer (Norland, USA).Results. There was a statistically significant increase in femoral neck BMD and T score as compared to the baseline values in the RTM group after 3 years of follow-up. The MT monotherapy group showed no statistically significant densitometric changes in the femoral neck. The similar positive BMD changes were observed 4 years following RTM and MT therapy.Conclusion. Following 2 therapy cycles, femoral neck BMD parameters were noted to be stabilized in the patients with RA. After 3 therapy cycles, there was a positive densitometric change that remained by the fourth therapy cycle.
format Article
id doaj-art-b1efbaea63514590bbefd9b2e3a7f733
institution Kabale University
issn 1996-7012
2310-158X
language Russian
publishDate 2015-09-01
publisher IMA-PRESS LLC
record_format Article
series Современная ревматология
spelling doaj-art-b1efbaea63514590bbefd9b2e3a7f7332025-08-20T03:59:57ZrusIMA-PRESS LLCСовременная ревматология1996-70122310-158X2015-09-0193162010.14412/1996-7012-2015-3-16-201927Time course of bone mineral density changes during 4-year rituximab therapy in postmenopausal women with rheumatoid arthritisT. A. Raskina0M. V. Koroleva1I. S. Dydykina2O. S. Malyshenko3G. A. Pintova4Kemerovo State Medical Academy, Ministry of Health of RussiaKemerovo State Medical Academy, Ministry of Health of RussiaV.A. Nasonova Research Institute of RheumatologyKemerovo State Medical Academy, Ministry of Health of RussiaResearch Institute for Complex Problems of Hygiene and Occupational DiseasesObjective: to estimate the time course of bone mineral density (BMD) changes during 4-year rituximab (RTM) therapy in postmenopausal women with rheumatoid arthritis (RA).Subjects and methods. Seventy-nine postmenopausal women with a valid diagnosis of RA were followed up. According to the basic therapy option, all the patients were allocated into two groups: 1) 44 patients who received combination therapy with RTM and methotrexate (MT); 2) 35 patients who had MT monotherapy. BMD was estimated by dual-energy X-ray absorptiometry using an Excell XR-46 stationary dualenergy X-ray bone densitometer (Norland, USA).Results. There was a statistically significant increase in femoral neck BMD and T score as compared to the baseline values in the RTM group after 3 years of follow-up. The MT monotherapy group showed no statistically significant densitometric changes in the femoral neck. The similar positive BMD changes were observed 4 years following RTM and MT therapy.Conclusion. Following 2 therapy cycles, femoral neck BMD parameters were noted to be stabilized in the patients with RA. After 3 therapy cycles, there was a positive densitometric change that remained by the fourth therapy cycle.https://mrj.ima-press.net/mrj/article/view/633postmenopausal womenrheumatoid arthritisosteoporosisbone mineral densityrituximab
spellingShingle T. A. Raskina
M. V. Koroleva
I. S. Dydykina
O. S. Malyshenko
G. A. Pintova
Time course of bone mineral density changes during 4-year rituximab therapy in postmenopausal women with rheumatoid arthritis
Современная ревматология
postmenopausal women
rheumatoid arthritis
osteoporosis
bone mineral density
rituximab
title Time course of bone mineral density changes during 4-year rituximab therapy in postmenopausal women with rheumatoid arthritis
title_full Time course of bone mineral density changes during 4-year rituximab therapy in postmenopausal women with rheumatoid arthritis
title_fullStr Time course of bone mineral density changes during 4-year rituximab therapy in postmenopausal women with rheumatoid arthritis
title_full_unstemmed Time course of bone mineral density changes during 4-year rituximab therapy in postmenopausal women with rheumatoid arthritis
title_short Time course of bone mineral density changes during 4-year rituximab therapy in postmenopausal women with rheumatoid arthritis
title_sort time course of bone mineral density changes during 4 year rituximab therapy in postmenopausal women with rheumatoid arthritis
topic postmenopausal women
rheumatoid arthritis
osteoporosis
bone mineral density
rituximab
url https://mrj.ima-press.net/mrj/article/view/633
work_keys_str_mv AT taraskina timecourseofbonemineraldensitychangesduring4yearrituximabtherapyinpostmenopausalwomenwithrheumatoidarthritis
AT mvkoroleva timecourseofbonemineraldensitychangesduring4yearrituximabtherapyinpostmenopausalwomenwithrheumatoidarthritis
AT isdydykina timecourseofbonemineraldensitychangesduring4yearrituximabtherapyinpostmenopausalwomenwithrheumatoidarthritis
AT osmalyshenko timecourseofbonemineraldensitychangesduring4yearrituximabtherapyinpostmenopausalwomenwithrheumatoidarthritis
AT gapintova timecourseofbonemineraldensitychangesduring4yearrituximabtherapyinpostmenopausalwomenwithrheumatoidarthritis